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Abstract
Fatal opioid overdose is a growing concern in the United States (U.S.). The pharmaceutical
companies assured the medical community that opioid pain relievers were not addictive. As a result,
providers prescribed them at a significantly higher rate, which led to more extensive use of authorized
and unauthorized opioid use before it was realized that they could be highly habit-forming (The U.S.
Department of Health and Human Services [HHS], 2019). A growing body of evidence supports providing
naloxone education as a means of harm reduction. The quality improvement project aims to implement
educational sessions for adult patients seen at East Bay Pain Management, who use prescription and nonprescription opioids, on naloxone and its benefits on reducing fatal opioid overdoses. The project lead
evaluates the effectiveness of naloxone educational sessions on improving participants’ knowledge of
naloxone and opioid overdoses and improving participants’ confidence in identifying an opioid overdose
event and acting on it.
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The Effects of Naloxone Education in Alameda County Among Adults
The prevalence of fatal drug overdose continues to increase in the U.S., as more than 700,000
Americans have died due to overdose on drugs between 1999 and 2017 (Centers for Disease Control
and Prevention [CDC], 2019). Approximately 68% of the over 70,200 fatal drug overdoses in 2017
contained an opioid. The daily death toll of Americans from opioid overdose averages 130 (CDC, 2019).
Pharmaceutical companies assured the medical community that opioid pain relievers were not addictive.
Thus, providers prescribed them at a significantly higher rate, which led to more extensive use of
authorized and unauthorized opioids, before it was realized that they could be highly habit-forming (HHS,
2019). High doses of opioids can suppress the drive to breathe and can be fatal (World Health
Organization [WHO], 2019). Illegally manufactured fentanyl, heroin, cocaine, or methamphetamines
accounted for approximately 85% of fatal drug overdoses in over 24 states and the District of Columbia
from the period of January to June of 2019 (CDC, 2020).
Naloxone is an inexpensive, nonscheduled opiate antagonist that can readily reverse the
respiratory depression and sedation caused by opioids (Sproler & Karl, 2007). Majority of accidental
overdoses happen in a home setting; hence, naloxone was made for first responders; in addition to
family, friends, and caregivers. No formal medical training is required to administer naloxone. Moreover,
naloxone is to be administered immediately for suspected or actual opioid overdose. It should not be
taking the place of emergency medical care. So, laypersons should get emergency medical help
immediately after administering the first dose of naloxone, even if the person wakes up (Narcan, 2021).
Opioid overdose has claimed the lives of approximately 47,000 persons in the United States in
2018 and resulted in high costs to the U.S economy. In 2017, the opioid epidemic cost the economy an
estimated $1,021 billion, including an estimated $471 billion in opioid use disorder and $550 billion in
cost of fatal opioid overdose. The CDC used national-level cost estimates to calculate the cost of opioid
use disorder and fatal opioid overdose for the state level in 2017 (Luo et al., 2021). The cases of opioid
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use disorder and fatal opioid overdose differ significantly among states. The purpose of this project is to
implement educational sessions to patients seen at East Bay Pain Management, to describe evidence
found to answer the following clinical question: Among adults who use prescription and non-prescription
opioids, will naloxone educational session, compared to no naloxone educational session increase
knowledge about opioid overdose, and increase knowledge and confidence in the use of naloxone, over a
three-month timeframe?
Problem Description
Opioid abuse has been a chronic epidemiological issue in the United States (U.S.). Pharmaceutical
companies assured the medical community that opioid pain relievers were not addictive. Providers
prescribed them at a significantly higher rate, leading to more extensive use of prescription and nonprescription opioids before the governing body realized that they could be highly addictive (HHS, 2019).
Because the brain controls breathing, opioids in high doses can cause respiratory depression and death
(WHO, 2019). Naloxone is an opiate antagonist with no potential for abuse. It is a nonscheduled drug that
can readily reverse the respiratory depression and sedation caused by opioids. The Drug Enforcement
Agency (DEA) recommended that clinicians prescribe naloxone to individuals at risk for opioid overdoses,
such as individuals who are on relatively high doses of opioids, take other medications prescriptions for
naloxone doubled from 2017 to 2018. Only one naloxone prescription is dispensed for every 70 high-dose
opioid prescriptions (WHO, 2019).
Alameda County recorded opioid-related mortality rates from a low of 1.6 per 100,000
residents in 2006, to a high of 8.5 per 100,000 residents in 2020. African Americans have the highest
mortality rate at 15.7 per 100,000. Among the opioid-related deaths, 10.3 per 100,000 were between the
ages of 25 to 34 years and 8.8 per 100,000 among males. Deaths from prescription overdose in Alameda
were 3.2 per 100,000 residence in 2014 (Alameda County Public Health [ACPH], 2021). Moreover, in
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Alameda County, deaths from opioid misuse tripled between 2005 and 2014 (Alameda County Health Care
Services Agency, n.d).
The project will target patients at East Bay Pain Management who use prescription and
non-prescription opioids. A knowledge deficit about naloxone was found among patients at the clinic after
a needs discussion with the CEO of the clinic hence the need to provide educational sessions to those
patients.
Setting
The project was implemented at East Bay Pain Management in San Leandro, Alameda County.
The project targeted patients at the clinic who use prescription and non-prescription opioids. A thorough
discussion with the medical director was done, which revealed a knowledge deficit about naloxone use
and patients’ confidence in using it, hence the need to provide educational sessions to those patients.
The clinic is privately owned and operated by Dr. Ernest Bonner. Dr. Bonner has practiced as a
Medical Doctor for 46 years and is board certified in addiction medicine. The patient population is
majority African American females from Alameda County seeking treatment for chronic pain. Payments
options for service are through Medical, cash, and some private insurances. Patients are from all
socioeconomic statuses, the majority are in their late 50s, and most have at least a high school level of
education.
Specific Aim
The aim of the quality improvement project is that, by December 2021, the project lead will
implement educational sessions on adults over 30 years, seen at East Bay Pain Management, who use
prescription and non-prescription opioids, on naloxone and its benefits reducing fatal opioid overdoses. In
addition, the project lead will evaluate the effectiveness of the naloxone educational session on
improving participants’ knowledge of naloxone and opioid overdoses and improving participants’
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confidence in identifying an opioid overdose event and acting on it. Thus, the objectives are to increase
understanding of naloxone’s potential to decrease fatal opioid overdoses and improve participants'
confidence in identifying an overdose event and acting on it.
Available Knowledge
PICOT Question
Population: Among adults Intervention: will naloxone educational session, Comparison:
compared to no naloxone educational session Outcome: increase knowledge about opioid overdose, and
increase knowledge and confidence in the use of naloxone, Time: over three months?
Search Method
An intensive search of Cochrane, Joanna Briggs, CINAHL, PubMed, and Scopus databases
yielded several articles. Topic and search terms such as “naloxone prescription program and opioid
overdoses,” “naloxone effectiveness,” “opioid overdoses,” “opioid overdose and naloxone prescription
program,” “naloxone take-home kits and opioid overdoses,” “naloxone take-home kits,” and “naloxone
take-home kit and peer administration.” Inclusion criteria of research articles in the U.S., ranging from
2015-2021. A total of 64 possible articles were yielded, of which eight were chosen for this project. The
remaining two articles were chosen from a similar article search option in CINAHL search. The systematic
review articles were selected since they are the highest level of evidence-based on the hierarchy of
evidence. Longitudinal cohort study, retrospective study, and a literature review were chosen as they
were related to the topic and higher on research evidence hierarchy than some unrelated studies, case
studies, and expert opinions found. The articles were appraised using the Johns Hopkins Nursing
Evidence-Based Practice Research Evidence Appraisal Tool (Dang & Dearholt, 2018).
Integrated Review of Literature
Chimbar & Moleta (2018), in their high-quality level II systematic review, aimed to explore the
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benefit of the naloxone prescription program, which includes educating participants about naloxone, on
decreasing opioid overdose deaths among users. Several major scholarly search engines were used to
explore studies that supported the aim, which initially yielded 118 studies. A total of nine studies met the
inclusion criteria. Information researchers extracted from the ten articles. Overall, the finding suggests
that take-home kits (THK) reduce the mortality rate from an opioid overdose. One study revealed a 98%
rate of successful rescue attempts, and another showed a confidence interval (Cl) of 95.5 upper estimates
and 97.1 lower estimates of successful opioid survival.
Another study revealed 96% upper estimates and 83% lower estimates of reduction in mortality
rate of opioid overdose. One limitation was due to unreported data from the studies. As a result,
further studies were recommended to include improved data collection methods and precisely follow up
periods from 3- 12 months when determining patient outcomes from THK compared to communities
that have no THK (Chimbar & Moleta, 2018).
McDonald & Strang (2016), in their level II high-quality systematic review, aimed to reveal
information about the usefulness of THK, which include educating participants about naloxone, the effect
of overdose deaths, and the safety of such programs. They performed a structured search of the
literature using the “PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)” as a
guide to extract information. They searched electronic databases to explore peer-reviewed studies issued
January 1946 and the third week in June 2015. Twenty-two articles met inclusion criteria. The articles
were analyzed and found to meet the nine Bradford Hill original criteria, which included experimental and
quasi-experimental evidence is known to be strong (McDonald and Strang, 2016). They concluded that
THK programs help reduce fatal opioid overdoses, lower the rate of adverse events, and are very costeffective. In total, 2249 of the 2336 THK administrations resulted in a successful overdose reversal (Cl of
95.5 upper estimates and 97.1 lower estimates of successful opioid survivals). However, bias in the
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selection process might have influenced the result since ten studies' outcomes depended on the followup to evaluate overdose events; only 22.9% of participants followed up (i.e., 1973 of 8602).
McAuley et al. (2015), in their level II high-quality systematic review, aimed to determine the
effects of take-home naloxone (THN) programs, including educating participants about naloxone on
opioid overdoses. They explored studies conducted from 1992 to 2014. They searched major scholarly
electronic databases and utilized specific search terms related to the topic. Studies that detailed THN
programs met the inclusion criteria and were selected or excluded if they failed to include information on
peers' overall outcome of the total naloxone administrations. They analyzed each study by utilizing the
“proportion of use (PoU)” approach to calculate the amount of naloxone given by a peer, the number of
candidates who received training, and supplies of naloxone. They focused mainly on persons who use
drugs over three months period.
McAuley et al. (2015) revealed that in the United States (U.S.), THN training could yield 35,000 to
88,000 uses every three months, which constitute the most significant number of lives potentially saved.
They also highlighted the application of THN based on the effects of opioids dosage and the increased
rate of enforcement that resulted in substantial reductions in overdoses mortality rates. McAuley et al.
(2015) recommended exploring the impacts from when participants received naloxone utilization training
to naloxone use. Moreover, a high-quality level of research must be a priority in future studies,
specifically comparing various training structures to determine relative effectiveness and utilize a series of
fixed periods from 3 to 12 months to test whether the time since training influences the rate of naloxone
use (McAuley et al. (2015).
Hanson et al. (2020), in their level III qualitative research, studied the effects of preventing opioid
overdoses by implementing a naloxone prescription program (NPP), which includes educating participants
about naloxone in rural Alaska. In 2017, the Alaska Department of Health and Social Services (DHSS) and
several other organizations in the community provided education on opioid overdose and distributed
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naloxone rescue kits to 18 laypersons. The participants were selected from two urban and two rural
communities and interviewed for approximately 17 minutes regarding the accessibility of naloxone,
naloxone training, overall knowledge, and prior use. The interviews were recorded and analyzed for the
correctness of the qualitative data (Hanson et al., 2020). They found success in the accessibility of
naloxone among participants, the nature of naloxone to reverse overdoses, overdose education, and
overall fatal overdoses based on participants' responses provided during the interviews (Hanson et al.,
2020). Participants feared arrest, stigma, housing, and custody issues if 911 was contacted, in addition to
some not trusting Alaska’s Good Samaritan Law. Hence, further studies are warranted to explore
differences in peers’ experiences related to gender and rurality, to explore other groups, and not solely
peers of opioid users, in receiving and giving naloxone (Hanson et al., 2020).
Siegler et al. (2017) conducted a longitudinal study that explored the effects of a naloxone
prescription program, which included educating participants about naloxone toward decreasing fatal
overdoses. Individuals who completed the training on preventing opioid overdose from June to
September 2013 were selected. Participants were chosen from six of the most extensive overdose
prevention programs in New York. Closed-ended questions were asked immediately after the training,
then at three months for six months, followed by 12 months after the training. Data were analyzed using
descriptive analysis, as well as bivariate and multivariate analysis, to reveal a possible link between
observing an overdose and giving naloxone. Logistic regression was utilized to compute the odds ratio,
95% confidence interval (Cl), and p-values to establish components associated with witnessing and
overdose compared to not witnessing an overdose. Moreover, associations with administering naloxone
compared to not administering naloxone during an overdose event (Siegler et al., 2017). A sensitivity
analysis was done to determine any statistically significant relationship between demography and
differences in drug uses over 12 months (Siegler et al., 2017). The researchers found that, of the 675
individuals who completed the overdose prevention training (OPT), 312 witnessed opioid overdoses, and
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naloxone was administered in 241 events (77%) by 188 (60%) of the OPT study participants.
Blacks/African American race vs. Hispanic, some college or college graduate versus less than high school
and witnessing an overdose in three months before the overdose prevention training were factors
associated with increased odds of witnessing an overdose. The adjusted odds ratio (AOR) = 2.41, 95% CI
1.22–4.76); 2.54, 95% CI 1.21–5.32); and 4.96, 95% CI 1.99–12.41), respectively. For participants who
witnessed an overdose, and syringe exchange program (SEP) participations, odds ratio (OR) = 2.91, 95% CI
1.25–6.77), and cocaine/crack use (OR) = 2.89, 95% CI 1.29–6.49 were linked to naloxone administration
in bivariable analysis. Still, none were statistically significant in multivariable analysis (Siegler et al., 2017).
Thus, there can be a tremendous impact on decreasing fatal opioid overdoses if participants likely to
observe and act on an overdose event are adequately trained (Siegler et al., 2017).
Equally important, when compared the participants who stayed in the study to those who left the
study, the ones who were lost to follow-up “were more likely to be Hispanic (73% vs. 54%, p = 0.006),
between 21 and 44 years old compared to those 45 and older (57% vs. 33%, p < 0.001), unstably housed
(30% vs. 16%, p = 0.017), and less likely to report the use of methadone (44% vs. 60%, p = 0.011)” (Siegler
et al., 2017).
There were discrepancies in the number of fatal opioid overdoses and rates of naloxone
administrations, in addition to the loss of valuable information limiting follow-ups and generalizability,
which all affected the reliability of the data (Siegler et al., 2017).
The researchers concluded that If naloxone distribution is prioritized and provided to a
population likely to witness an event, the impact on opioid overdose mortality will be tremendous.
Moreover, population training is recommended to target an adequate number of candidates likely to
observe and act on an overdose event to decrease the number of fatal opioid overdoses (Siegler et al.,
2017).
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Mitchell & Higgins (2016), in their level III literature review of 38 articles, sought to identify the
effects of public access to naloxone and the effects on fatal opioid overdose. They found that several
international countries and states in the U.S. recorded success in reversal rates using NPP, which included
educating participants about naloxone. In one study, 152,283 candidates received THK after training on
opioid overdose; 26,463 overdoses were reversed. Equally important, another showed an 89% success
rate in reversals. Some limitations of the study were due to stigma associated with illicit users, which
could affect the reliability of the result if participants fail to report findings or follow up. Moreover,
providers were reluctant to prescribe due to fear of liability issues. The high price of naloxone
forced users to seek more affordable forms or discouraged use. Well-renowned organizations, including
the Office of National Drug Control Policy, support NPP recommended intranasal naloxone due to its
safety, protocol implementation for naloxone distribution, legislative reform, and holistic approach in
preventing overdoses.
Wheeler et al. (2015) level III literature review, assessed a survey conducted by the Harm
Reduction Coalition (HRC) on 140 organizations in the United States that supply naloxone to laypersons.
HRC aimed to determine the effects of NPP on fatal opioid overdoses from 1996 through June 2014. The
NPP includes educating participants about naloxone. The research results included 136 organizations that
responded to the survey and revealed that a total of 152,283 naloxone kits were given to laypersons, of
which 26,463 reported successful reversals in opioid overdoses. The researchers concluded that if
training for opioid overdose events and naloxone rescue kits are provided to candidates who are likely to
witness an opioid overdose, fatal opioid overdoses can be reduced. Further studies are recommended to
include laypersons likely to observe an overdose.
Ogeil et al. (2018) conducted a retrospective review to assess the effects of THN on the impact of
fatal opioid overdoses. This study was appraised as level III evidence. The researchers reviewed
pharmaceutical overdose deaths records from January 2011 to December 2013 from Coroners Court
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Victoria in South-Eastern Australia. There were 125 participants, 69.6% males ranging from 16-65 years
and 30.4% female with ages ranging from 22-63 years. Descriptive statistics was used to analyze the
results. It was evident in more than 20% of the deaths that a witness, mainly partners or acquaintances,
noticed common signs related to overdose. Those witnesses were prepared to administer naloxone as
first aid. However, in 70.4% of the cases, the witnesses did not act even though they noticed probable
overdose symptoms. The study revealed that overdose education and naloxone administration to
layperson including families must be implemented to reduce fatal opioid overdoses. A limitation is that
witnesses present at the initial stage of the overdose might not have been questioned or included in the
coroner report. Another is that witnesses might withhold information to avoid any law enforcement
interaction. Overall, the generalizability and validity of the findings may be affected when witnesses are
absent or withhold information.
Furlan et al. (2018) carried out a level II high-quality systematic review of peer-reviews and
untraditional published literature that sought the correlation between approaches to monitor the
proper use of opioids and reducing fatal opioid overdoses. A total of 65 studies were used to extract
information: 9 randomized trials and 56 were non-randomized, and 66 specific strategies were identified.
The strategies covered areas such as educational, clinical practice, distribution of naloxone, therapies on
opioid substitution therapies, prescription monitoring, campaigns focused on returning of unused
opioids, regulations, policies and public movements or campaigns. PRISMA checklist was utilized,
systematic quantitative review including Cohen’s d tests, were done to analyze the result.
Twenty-two studies evaluated the impact of several strategies on overdose and deaths, with
effects ranged between -3 to 3. Implementation of an opioid dosage guideline had the most considerable
negative impact resulted in a significant increase in mortality due to methadone. On the other hand, four
strategies had a significant positive effect that included overdose prevention training and naloxone
distribution, changes in the legal status of naloxone permitting its administration by any member of the
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public, and pharmacy-based naloxone distribution in addition to education and training. Equally
important opioid substitution, primary care involvement, THN and training program had a significant
positive effect. Naloxone distribution was the most common approach to decreasing fatal opioid
overdoses with largely positive feedback.
Some limitations were selection bias and poor participant follow-up: for example, one study
reported a 39% dropout rate. Another problem was that the study was unclear about the groups selected
for the study. Therefore, further studies are recommended to include an adequate description of the
study groups, limiting the risk for bias.
Mueller et al. (2015), in their level III literature review, sought to reveal the effects of community
naloxone prescription program on opioid overdose. The NPP includes educating participants about
naloxone. A total of 41 articles were obtained from PubMed were used in the research. PRISMA was used
to condense the studies. One study found that naloxone administration was influential with an 86%
reversal rate; another reported an 80% reversal rate. Some limitations were related to some witnesses
not being comfortable administering naloxone, and prescribers were not willing to prescribe naloxone. In
addition, they underreported data due to possible legal implications associated with reporting to law
enforcement. See Appendix C for the evaluation table on the literature above.
Synthesis of the Evidence
After reviewing the evidence of the ten research articles, the naloxone prescription program
consistently demonstrated a decrease in opioid overdose mortality rates in five of the articles. The
naloxone prescription program entails educating laypersons on identifying and managing opioid overdose
and distributing naloxone rescue kits to the attendees. The other five articles revealed a high chance of
reducing fatal opioid overdoses if training is provided on opioid overdose and THK is given to candidates
attending the training, who are more likely to observe and act on an overdose. Further research was
recommended to include improved data collection, and follow-up periods collectively from 3-12 months
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after participants received naloxone education. In addition, population training should target participants
more likely to witness and act on an overdose event.
One of the main strengths contributing to the validity and reliability of the findings was consistent
with the level of evidence found. They were mainly systematic reviews, with one using meta-analysis to
support the evidence. Systematic reviews are known to have the most rigorous approach to limit bias in
condensing research (Melnyk & Fineout-Overholt, 2019, p. 171). A meta-analysis uses a statistical process
to generate new evidence from the available data. Most of the studies were within the past five years,
which adds to relevancy and appropriateness when implementing the findings.
The inconsistencies were mainly with selecting and analyzing data from the various studies. Even
though there were consistencies in the overall findings, each selection and or analysis method has
limitations that can impact the overall findings. For example, two of the ten studies revealed participants
feared arrest, stigma, housing, and custody issues if 911 was contacted. Another study done in Alaska
revealed a lack of trust in the Good Samaritan Law. Further interventions should help raise awareness of
the Good Samaritan Law to decrease the trust issues.
Even though the studies highlighted several limitations, consensus on the significant conclusion
was evenly split. Five of the studies revealed NPP consistently decreased opioid overdose mortality. The
other five articles revealed a high chance of reduction in fatal opioid overdoses if the educational session
is provided on opioid overdose.
To decrease fatal opioid overdoses medical facilities should utilize the concept of naloxone
education through a prescription program. In addition, NPP should ensure implementation of opioid
overdose education and training of persons with higher chances of observing an opioid overdose event
and acting on it. Further studies are needed to yield more consistent information as Nurse Practitioners
(NPs) depend on consistent and reliable evidence to advocate educational sessions through NPP in
medical facilities. NPs should become familiar with NPPs and educational sessions considering the
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associated benefits to patient outcomes and become more engaged with policy proposals that target
such educational programs implementations. In addition, NPs should prescribe naloxone to patients at
risk for an opioid overdose to help decrease the opioid overdose mortality rate. NPs should also be
involved in teaching efforts on proper usage of naloxone, including signs and symptoms of opioid
overdose, to ensure patients are adequately informed. Lastly, NPs should be aware of the stigmas
associated with opioid use disorder and engage in continuing education sessions to improve knowledge.
Rationale
The Cascade of Care model was used as a guide for this project. This model was used to identify
participants who use naloxone. Also, the Cascade of Care model was used to enhance treatment
outcomes with naloxone educational sessions to decrease related diseases and deaths. The model has
four cascades: the prevention, identification, treatment, and recovery phase. The aim is to prevent opioid
overdose, identify patients at risk for addiction and overdose, provide educational sessions, all phases
eventually leading to recovery (National Institute of Drug Abuse (NIH), 2019). This framework fits well
with the population, and it is simple to comprehend and self-explanatory to readers (see Appendix N).
Nola J. Pender’s Health Promotion Model (HPM) was used to guide the project (see
Appendix P). Nola Pender began to work on the model in the mid -1970s, then published it in
1982. The model provided a multifaceted approach to a person’s life regarding their
environmental interaction in the quest to pursue optima l health (McEwen & Wills, 2011).
There are several concepts and definitions of the Health Promotion Model, including
personal factors, perceived benefit to action, barriers to action, self -efficacy, and activity-related
effect. In addition, there are interpersonal and situational influences, commitment to the action
plan, immediate competing demands and preferences, and health-promoting behavior (McEwen
& Wills, 2011).
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This project highlighted perceived self-efficacy and health-promoting behaviors.
Perceived self-efficacy is related to a person’s confidence to do something. In the case of the
project, the participants developed knowledge and confidence in identifying an opioid overdose
event and acting on it. Health-promoting behaviors are outcomes of action “directed towards
attaining positive health outcome” such as optimal well-being, personal fulfillment, and
productive living” (Current Nursing, 2011). In the case of the project, the participants developed
the knowledge and ability to safely and effectively use naloxone to reverse opioid overdoses.
The Health Promotion Model guided the project as the lead explored the effects of
naloxone educational sessions among participants. It gave a better understanding of the
approaches to promoting health on an individual level. Each person is unique and has a
perception of health promotion. Understanding ways in which individuals view health or health
promotion was beneficial.
This HPM helped explain how naloxone educational sessions can increase confidence in
identifying an opioid overdose event and acting on it. Participants were readily available to
change distorted perceptions about naloxone, mainly because the project lead presented
evidence-based information to them. The HPM guided each phase of the project by helping to
influence health-promoting behavior while seeking to gather information. The project lead
approached each stage of the project with the knowledge that “health -promoting behaviors are
useful to promote health state” (Chinn & Kramer, 2018, p 283). Utilizing the HPM assisted to
identify variables to measure both dependent and independent variables. In addition, it allowed
the project to consider independent variables such as prescription opioids, naloxone educational
sessions, and location.
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Interventions
A gap analysis was used to determine the current gap that revealed a need for naloxone
educational sessions. The developmental plan was to implement naloxone educational sessions to
increase knowledge about opioid overdose and increase knowledge and confidence in using naloxone.
The Gantt chart was used to maintain the specified timeline of the project’s success in moving forward. In
addition, adjustments were made throughout the project to ensure that it moves forward to completion.
The work breakdown structure was used to outline the component of the project, which included the
project’s introduction, planning development, implementation, and data analysis and evaluation. The
responsibility/communication plan was used to outline communication throughout the project with the
DNP chairman and committee member via email and zoom meetings as needed. Equally important,
communication was done by telephone and in-person visit with the site medical director and other clinic
staff. Finally, a strengths, weaknesses, opportunities, and threats (SWOT) analysis was used to assess the
project's strengths, weaknesses, opportunities, and threats.
Gap Analysis
Fatal opioid overdose is a growing concern in the U.S (HHS, 2019). Alameda County recorded an
opioid-related mortality rate from a low of 1.6 per 100,000 residents in 2006, to a high of 8.5 per 100,000
residents in 2020. African Americans have the highest mortality rate at 15.7 per 100,000. Among the
opioid-related deaths, 10.3 per 100,000 were between the ages of 25 to 34 years and 8.8 per 100,000
among males (Alameda County Public Health [ACPH], 2021).
Currently, clients at risk for opioid overdose have no educational program on naloxone use, and
the desire is to increase knowledge and confidence in the use of naloxone. After the gap analysis was
completed, it revealed that there was a need for naloxone educational sessions. Therefore, the
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developmental plan was to implement naloxone educational sessions to increase knowledge about opioid
overdose and increase knowledge and confidence in using naloxone (see appendix D).
Gantt Chart
The milestones for this project were identified using a GANTT chart to guide the projected
timelines (see Appendix E). This GANTT chart maintained the specified timeline of the project’s success in
moving forward. In addition, adjustments were made throughout the project to ensure that it moves
forward to completion.
The timeline spans from August 2021 to December 2021. Several meetings were held in 08/2021
with the chief executive officer (CEO)/medical director to achieve buy-in, formulating a committee with
the medical director and psychiatric/medical assistant. Equally important, meetings were held with the
DNP chair and committee members to discuss the project plan and obtain approval. Educational materials
were gathered. In September 2021, further discussions were held with the CEO for project plan approval,
a letter of support from the organization was obtained, and educational sessions were initiated. Process
evaluation and reviews of the appropriateness of the patient training materials were done periodically
throughout the six weeks period from September to October 2021. Data from the project was gathered,
and preparation of the manuscript began in October and spanning to December for the DNP
presentation. The project will be left open for any psychiatric mental health nurse practitioner (PMHNP)
student who has an interest and willingness to carry out further quality improvement projects on the
topic (see Appendix E).
Work Breakdown Structure
The goal was to provide educational sessions on naloxone to adults who use prescription and
non-prescription opioids and their benefits in reducing fatal opioid overdoses. The overall objectives are
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to increase understanding of naloxone’s potential to decrease fatal opioid overdoses and improve
participants' confidence in identifying an overdose event and acting on it. To implement the project lead’s
role in the community setting and establish the tasks necessary to meet the project’s, a WBS was
necessary (see Appendix F).
The responsibilities associated with meeting the project lead’s goal started with meeting with the
chief executive officer (CEO)/medical director to achieve buy-in, formulating a committee with the
medical director and psychiatric/medical assistant. Once the medical director supported the project
proposal, the project lead obtained the letter of support granting permission to implement the project
(see Appendix B). Finally, the project lead gathered evidence-based naloxone educational material on
administering naloxone (see Appendix O), including a sample naloxone kit and printouts on naloxone
spray quick start guide with opioid overdose response instructions was provided to those who attended
the educational sessions (see Appendix L).
Staff education/communication was done on the education process, and help was received to
randomly select the participants. Then, the trial began by educating 40 participants: at 5-10 patients per
clinical day for a total of 6 weeks. Next, each participant completed pre-questionnaires with the help of
the psychiatric assistant if available in the clinic. Next, the project lead provided the naloxone educational
sessions, followed by a post questionnaire to evaluate the effectiveness of each session. Finally, the
process evaluation was performed, and a measurable value was established that revealed the progress of
the outcome or outcome metrics (see appendix Q).
Periodical reviews of the appropriateness of patient training materials at each visit were done,
and changes were made when necessary. The project lead also maintained monitoring of outcome
metrics to determine the effectiveness of the education sessions, formulated reports for stakeholders on
data collected from the project, prepared the manuscript to be presented at the Doctor of Nursing
Practice (DNP) project presentation.
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Responsibility/Communication plan
Communication was done throughout the project with the DNP chairman and committee
member via email and zoom meetings as needed. Equally important, communication was done by
telephone and in-person office visits with the site medical director and other clinic staff (see Appendix G).
SWOT Analysis
A strength, weaknesses, opportunities, and threats (SWOT) analysis was conducted to identify
the strengths, weaknesses, opportunities, and threats of implementing the naloxone education sessions
(see Appendix H). There is evidence-based research to support the implementation of naloxone
educational sessions. A review of the literature demonstrated the benefits garnered through various NPP,
such as the decreased rate of opioid overdoses. Some of the benefits are that the educational sessions
are available for participants likely to witness an opioid overdose event and act on it. Moreover,
participants likely to see an opioid overdose event will gain knowledge and confidence. Thus, there will be
an opportunity for harm reduction with the decreasing opioid overdose rate. Furthermore, participants
willing to help in an opioid overdose can help with the knowledge and confidence gained from the
educational session. Other strengths are related to stakeholders’ support. Each naloxone kit comes with a
handout with steps on administering naloxone if participants need a refresher on how to use naloxone.
Some weaknesses are that naloxone kits will not be distributed during the educational sessions,
thus limiting accessibility for naloxone. In addition, participants who will likely witness an opioid overdose
and act on it might not want to partake in the educational sessions. Equally important, participants might
be afraid of legal issues due to limited knowledge about the Good Samaritan Law in California (see
Appendix M), and the clinic might be against the proposal.
After all, some opportunities for harm reduction are that the educational sessions will allow
participants to provide help and save a life, possibly the lives of family or close friends. Moreover, the
convenience of educational sessions via telephone call while participants are in a convenient setting.
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Lastly, some threats are that participants might not want to answer an unknown call; thus, the
targeted goal of 40 participants could have been affected.
Budget and Financial Analysis
There was an operating budget of $4 from August 2021 to December 2021. If the project
continues, the projected cost for staff would be as follows: nurse practitioner who will provide the
educational sessions, estimated for 2 hrs weekly x $85 per hr for six weeks = $1020. Moreover, the
psychiatric assistant who will assist with gathering educational materials and selecting participants is
estimated for 1 hr weekly x $15 per hr for six weeks = $90. Hence, the total cost was $1,114 for six weeks.
If the project goes beyond December 2021, the operating budget will be around $2228 annually for year
two and $4456 for year 3. Years two and three are budget propositions in the case of another DNP
student interested in the topic and would like to continue with the project over three months, six months,
respectively. Some requirements for the project were already in place by the clinic, including staffing and
infrastructure. Therefore, the project will not yield revenue or return on investment (ROI) over the
implemented period. However, the project is expected to show participants’ increased understanding of
naloxone’s potential to decrease fatal opioid overdoses and improve participants' confidence in
identifying an overdose event acting on it, thus harm reduction (see Appendix I).
Outcome Measures
Pre and post Interviews questionnaires (quantitative and qualitative questions) were provided to
participants to determine participants’ knowledge about the benefits of naloxone on reducing fatal
overdoses, participants' confidence level to identify an opioid overdose event and act on it. Also,
participants learned about the Good California Samaritan Law, the benefits of the educational sessions,
and indications of each participant’s success in using naloxone. The data was analyzed using SPSS. T-test
was used to determine the difference between pre-and post-naloxone education on participants’
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knowledge. Descriptive statistics was used to summarize the data. Software: Microsoft Excel data analysis
program was used for logging data collected.
Data Collection Tools
Pre and post-test administered to measure knowledge of naloxone and opioid overdoses and
confidence to identify an opioid overdose event. The data was logged in Microsoft Excel and stored as
numbers.
Analysis
Demographics
There were 40 participants in the project and 11 (27.5%) identified as male and 29 (72.5%)
identified as female (Table 1). For race, most participants identified as Black or African American (n = 33,
82.5%) followed by Other (n = 4, 10.0%), Hispanic (n = 2, 5.0%), and Caucasian (n = 1, 2.5%). On age, most
participants reported being 50-79 (n = 20, 50.0%) or 30-39 (n = 19, 47.5%) years old followed by 79 and
above (n = 1, 2.5%). All participants reported residing in Alameda County (n = 40, 100%). Finally, most
reported their visit was by telephone (n = 31, 77.5%) and the rest in the office (n = 9, 22.5%).
Table 1
Participant Demographics
Question
What is your gender?

N

%

Male

11

27.5%

Female

29

72.5%

Black or African American

33

82.5%

Caucasian

1

2.5%

Hispanic

2

5.0%

What is your race?
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Other

4

10.0%

30-49

19

47.5%

50-79

20

50.0%

79 and above

1

2.5%

Alameda

40

100%

Other

0

0%

Office

9

22.5%

Telephone

31

77.5%

I am between the ages of:

What county do you live?

Type of visit?

Descriptive Statistics
As seen in Table 2, most participants reported using opioids (n = 27, 67.5%) and the rest reported
no use (n = 13, 32.5%). Many participants (n = 12, 30.0%) reported using Oxycodone (Percocet) while 12
(30.0%) reported no type of opioid use followed by Hydrocodone (n = 9, 22.5%), and the rest (n = 7,
17.5%) used more than one opioid. Many reported that they did not use other controlled substances (n =
36, 90.0%) and had never had or witnessed an overdose event (n = 26, 65.0%). When asked about
accessing Naloxone, 20 (50.0%) reported yes, while 19 (47.5%) reported no. When asked about using
non-prescription opioids, all participants, 40 (100%), reported no use. Most participants did not have a
designated person to assist them in case of an overdose (n = 23, 57.5%), while 17 (42.5%) did have a
designated person. When asked if the designated person was trained on using Naloxone, 17 (42.5%)
reported yes. Finally, the pharmacist did not show most participants (n = 24, 60.0%) how to use Naloxone
based on the responses.
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Table 2
Participant Reports About Opioid Experience and Usage
Question
Do you use opioids?

N

%

Yes

27

67.5%

No

13

32.5%

Fentanyl, Oxycodone (Percocet)

1

2.5%

Hydrocodone (Norco)

9

22.5%

Hydrocodone (Norco), Morphine

1

2.5%

None

12

30.0%

Oxycodone (Percocet)

12

30.0%

Oxycodone (Percocet), Hydrocodone (Norco)

3

7.5%

Oxycodone (Percocet), Methadone, Morphine

1

2.5%

Oxycodone (Percocet), Oxycontin

1

2.5%

No Answer

1

2.5%

Yes

3

7.5%

No

36

90.0%

Yes

14

35.0%

No

26

65.0%

20

50.0%

Name the type (s) of opioids that you use?

Do you use other controlled substances?

Have you ever had or witnessed an opioid overdose event?

Do you know where to access naloxone in your county
without the need for a prescription?
Yes

28

No

19

47.5%

No Answer

1

2.5%

Yes

17

42.5%

No

23

57.5%

Yes

17

42.5%

No

23

57.5%

Yes

16

40.0%

No

24

60.0%

Do you have a designated person in case of an overdose?

If so, has the designated person been trained how to use naloxone?

Has the pharmacist shown you how to use naloxone?

Ethical Considerations
Several ethical issues might arise from implementing the educational sessions due to the
nature of the medication and targeted population. Based on evidence-based research, it has
been proposed that NPPs can decrease opioid overdoses. An ethical issue regarding the project
was assessed from a practical perspective. The educational sessions were advantageous to
participants taking opioids and having a naloxone prescription or yet to receive one. Naloxone is
a safe drug with no potential for abuse (Darke & Hall, 1997). However, there can be some medicolegal complications associated with medical providers prescribing naloxone that participants will be given
to and by individuals other than the prescribed person. Moreover, the economic cost of distributing
naloxone for free on a broader scale. Nevertheless, considering its impact on overdose morbidity and
mortality and the prospective higher price-effectiveness of more direct educational interventions, it may
be worth the consideration (Darke & Hall, 1997).

29

Patients have the right to veracity. Veracity is the duty to tell the truth (American Nurses
Association [ANA], 2015). Participants were provided with truthful and accurate information
about the project before gaining their consent. Also, participants were taught factual and
evidence-based information. Participants have the right to confidentiality (ANA, 2015).
Therefore, numbers were used as identifiers to protect participants’ information .
Finally, the project took into consideration and incorporated the ethical values of the University
of San Francisco. The values to be considered are cura personalis that means caring holistically for
patients. The project lead ensured to offer support and care to participants. All the participants' questions
were answered in a caring and respectful manner. Patients’ understanding of the educational sessions
were assessed, and corrections were made when necessary. Moreover, being available for others and
committed to diversity (University of San Francisco, 2021). Cultural competence was always practiced
ensuring effective and appropriate communication during the sessions.
Results
Pre-and post-questionnaires were administered to measure knowledge of naloxone and opioid
overdoses and confidence to identify an opioid overdose event. The pre-test had an average score of
1.95 (SD = 2.037), and the post-test average score was 5.00 (SD = .000). Based on the responses, the
post-test score was found to be significantly higher than the pre-test score at t (39) = -9.468, p < .001
(Table 4). As a result, the intervention was successful in being statistically significant in raising knowledge
and confidence (Figure 1).
Table 3
Paired Samples Statistics for Knowledge and Confidence

Pre-Test score

M

N

SD

1.95

40

2.037

30

Post-Test score

5.00

40

.000

Table 4
Paired Samples T-Test for Knowledge and Confidence

95% Confidence
Interval of the Difference
M

SD

-3.05

2.037

Lower

Upper

t

df

p

-9.468

39

.000

Knowledge and
Confidence

-3.70

-2.39

Figure 1
Knowledge and Confidence Mean Scores

Note. A bar graph illustrating the pre-and post-test mean score of knowledge and confidence.
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Discussions
Summary and Interpretation
Firstly, THK decreases the mortality rate from an opioid overdose. One study revealed a 98% rate
of successful rescue attempts. Another showed a confidence interval (Cl) of 95.5 upper estimates and
97.1 lower estimates of successful opioid survival (Chimbar & Moleta, 2018).
Secondly, THK programs help reduce fatal opioid overdoses, lower the rate of adverse events,
and are very cost-effective. Findings revealed Cl of 95.5 upper estimates and 97.1 lower estimates of
successful opioid survivals (McDonald & Strang, 2016).
Thirdly, THN training could yield up to 88,000 uses every three months, constituting the most
significant number of lives potentially saved. Moreover, substantial reductions in overdoses mortality
rates can result from the implementation of THN (McAuley et al., 2015)
Fourthly, there was success in the accessibility of naloxone among participants, the nature of
naloxone to reverse overdoses, overdose education, and overall fatal overdoses based on participants'
responses during the interviews (Hanson et al., 2020).
Equally important, there can be a tremendous impact on decreasing fatal opioid overdoses if
participants are adequately trained to observe and act on an overdose event. Moreover, If naloxone
distribution is prioritized and provided to a population likely to witness an event, the impact on opioid
overdose mortality will be tremendous (Siegler et al., 2017). In another study, 152,283 candidates
received THK after training on opioid overdose; 26,463 overdoses were reversed. Moreover, another
showed an 89% success rate in reversals (Mitchell & Higgins, 2016).
Moreover, if training for opioid overdose events and naloxone rescue kits are provided to
candidates who are likely to witness an opioid overdose, fatal opioid overdoses can be reduced (Wheeler
et al., 2015). Equally important, overdose education and naloxone administration to laypersons including
families, must be implemented to reduce fatal opioid overdoses (Ogeil et al., 2018).
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Naloxone distribution was the most common approach to decreasing fatal opioid overdoses with
largely positive feedback (Furlan et al., 2018). Finally, naloxone administration was influential with an 86%
reversal rate; another reported an 80% reversal rate (Mueller et al., 2015).
Educating adults who use prescription and non-prescription opioids on naloxone and its benefits
in reducing fatal opioid overdoses was a success. The approach increased understanding of naloxone’s
potential for decreasing fatal opioid overdoses and improved participants' confidence in identifying an
overdose event and acting on it.
By the end of the six weeks educational sessions, all 40 participants became more knowledgeable
about the benefits of naloxone on reducing fatal opioid overdoses. There was an increase in confidence
level in the ability to identify an opioid overdose event, and an increase in confidence level in the ability
to act on an opioid overdose event. In addition, all patients became knowledgeable or improved their
knowledge about the California Good Samaritan Law and successfully demonstrated/verbalized how to
use naloxone.
Limitations
Some limitations to this project were garnering clinic staff support for the program. The student
has contacted several clinics before receiving approval for the project by Dr. Bonner, CEO at East Bay Pain
Management. Moreover, some participants likely to witness an opioid overdose and act on it might not
have been selected to partake in the program. In addition, some participants were reluctant to disclose
information during the telephone conversations because some participants thought the project lead was
a telemarketer. Moreover, participants' bias and lack of trust might have affected the findings, as some
participants might have feared that providing information for the project would affect their opioid
prescription or refills; thus, some participants might falsify their responses to avoid such issues.
Conclusion
The implementation of the naloxone educational sessions was found to be valuable in helping to
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combat the current opioid crisis. The ability of the sessions to educate adults who use prescription and
non-prescription opioids on naloxone and its benefits on reducing fatal opioid overdoses is a crucial need.
The naloxone educational sessions effectively improved participants' knowledge of naloxone and opioid
overdoses and improved participants' confidence in identifying an opioid overdose event and acting on it.
All the participants increased their understanding of naloxone’s potential to decrease fatal opioid
overdoses and improve participants' confidence in identifying an overdose event and acting on it.
Considering the results from the literature review and statistical findings from the quality
improvement project, medical facilities should utilize the concept of naloxone educational sessions to
increase participants' knowledge and confidence. In addition, NPs should ensure the implementation of
opioid overdose education and training of persons with higher chances of observing an opioid overdose
event and acting on it. NPs should become familiar with NPPs and educational sessions considering the
associated benefits to patient outcomes and become more engaged with policy proposals that target
such educational program implementations. In addition, NPs should prescribe naloxone to patients at risk
for an opioid overdose to help decrease the opioid overdose mortality rate. NPs should also be involved
in teaching efforts on proper usage of naloxone, including signs and symptoms of opioid overdose, to
ensure patients are adequately informed. NPs should also limit the stigmas associated with opioid use
disorder by completing continuing education courses on opioid use and misuse. Lastly, further studies are
needed to assess the benefits of naloxone educational sessions over more extended periods and possibly
incorporate naloxone distributions.
Funding
No funding was provided for this project. Instead, personal funds were used to purchase copies
of the naloxone nasal spray quick start guide.
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Appendix C
Evaluation Table
Chimbar & Moleta (2018)
Purpose of
Article or
Review

Conceptual
Framework

Explore the
benefit of
NPP
on decreasing
opioid
overdose
deaths among
users.

Searched
studies,
identified, and
selected
studies to
include, data
extracted and
synthesized,
interpreted,
then shared
result.

Design /
Method

Systemic
review

Sample /
Setting

Major
Variables
Studied
(and their
Definitions)

Measurement
of Major
Variables

Scholarly
searched
engines

Opioid drug
users

Naloxone
prescription
program

Data
Analysis

Inclusion
and
exclusion
criteria

Study
Findings

Take-home
naloxone kits
(THK) reduce
the rate of
mortality
from opioid
overdose

Level of Evidence (Critical Appraisal
Score) /
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Mixed method, high-quality level II
systemic review.
THK is worth the practice.
Conclusion:
THK reduces the rate of mortality from
an opioid overdose.
Recommendations:
Include improved data collection
method and specific follow-up periods
from 3- 12 months when determining
THK patient outcomes compared to
communities with no THK.

Definition of abbreviations:
NPP- Naloxone prescription program.
THK- Take-home naloxone kits

McDonald & Strang (2016)
Purpose of Article
or Review

Conceptual
Framework

Aimed to reveal
information
about the
the usefulness of
THK, the effect of
overdose deaths,
and the safety of
such program
regarding adverse
events.

Searched
studies,
identified, and
selected studies
to include, data
extracted and
synthesized,
interpreted,
then shared
result.

Design /
Method

Systemic
review

Sample /
Setting

n=22,
Scholarly
electronic
databases

Major
Variables
Studied (and
their
Definitions)

Opioid drug
users and
naloxone
prescription
program

Measurement
of Major
Variables

Inclusion
and
exclusion
criteria,
PRISMA

Data
Analysis

Bradford Hill
criteria

Study
Findings

THK
program
helps to
reduce fatal
opioid
overdoses,
lower the
rate of
adverse
events, and
very costeffective.

Definition of abbreviations:
THK: Take-home naloxone
Bradford Hill Criteria: A total of 9 concepts were used to examine cause and effects.
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses. It was used as a guideline to extract inform

Level of Evidence (Critical Appraisal
Score) /
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Level II, high quality, systematic
review.
THK program helps to reduce fatal
opioid overdoses, lower the rate of
adverse events, and is very costeffective.
Selection bias and lack of follow-up
may have affected the study result.
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Evaluation Table (continued)
McAuley, Aucott, & Matheson (2015)
Purpose of
Article or
Review

Conceptual
Framework

Aimed to
determine the
effects of THN
programs on
opioid
overdoses

Searched studies,
identified, and
selected studies
to include, data
extracted and
synthesized,
interpreted, then
shared result

Design /
Method

Sample /
Setting

Major Variables
Studied (and
their
Definitions)

Measurement
of Major
Variables

Systematic
Review

Scholarly
searched
engines
for studies
in the
English
language
between
1992 and
2014

THN programs,
participants
trained and
supplied with
naloxone,
persons who use
drugs

Gender, sex,
persons who
use drugs

Data
Analysis

PoU

Study
Findings

The
enforcement
of THN with a
dose-related
effect and
increased
rate of
enforcement
resulted in
substantial
reductions in
overdoses
mortality
rates.

Level of Evidence (Critical
Appraisal Score) /
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Mixed method, level II, high
quality, Systemic Review
They recommended exploration
of the effects
from the time participants
received naloxone utilization
training to the overdose time,
high-quality research must be a
priority in future studies.
The PoU method to validate
peers reports in future studies

Definition of abbreviations:
THN: Take-home naloxone
PoU: Proportion of use. It was used to calculate the amount of naloxone given by a peer, the number of candidates who received training, and
supplies of naloxone.

Hanson et al. (2020)
Purpose of Article
or Review

Conceptual
Framework

Design /
Method

Sample
/
Setting

Major
Variables
Studied
(and their
Definitions)

Measurement
of Major
Variables

Data Analysis

Study
Findings

Explore the
effects of
preventing opioid
over-doses
through NPP in
rural Alaska

Identify target
population,
interview
participants,
synthesize
data, interpret,
then share the
result.

Semistructured
interview
Participants
selected from
2 urban and
two rural
Communities
and
interviewed
for
approximately
17 minutes

Rural
Alaska

Age, sex,
race, rurality
of 18
laypeople
who
received
opioid
overdose
rescue kits
from project
HOPE and
administered
naloxone to
a peer.

Participants
must attend
the class and
be
administered
naloxone
before.

Interviews
were audiorecorded,
transcribed
verbatim,
and then
reviewed and
edited for
accuracy.”
(Hanson et
al., 2020).

Success in
the
accessibility
of naloxone
among
participants,
nature of
naloxone to
reverse
overdoses,
overdose
education,
overall
“harm
reduction.”

Definition of abbreviations: Project HOPE: is a program that provides opioid overdose education and distributes naloxone

Level of Evidence (Critical Appraisal
Score) /
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Level III, good quality, qualitative
study.
Further studies are warranted to
explore differences in peers'
experiences related to gender and
“rurality” They explore other groups
in receiving and administering
naloxones, such as first responders
or law enforcement and not peer
users alone (Hanson et al. 2020).
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Evaluation Table (continued)
Siegler et al. (2017)
Purpose of Article
or Review

To explore the
effect of the
Naloxone
prescription
program on
decreasing fatal
opioid overdose

Conceptual
Framework

Design /
Method

Sample /
Setting

Major
Variables
Studied (and
their
Definitions)

Measure
ment of
Major
Variables

Data Analysis

Study Findings

Identify study
participants,
observe
participants,
collect, and
analyze data,
interpret
data, then
share the
result.

Longitudinal
Cohort
Study.

Six of the
largest
opioid
overdose
prevention
programs in
New York.
n= 321

Participants
who
completed
OPT, baseline
questionnaire,
3-12 months
questionnaire,
18 yrs. or
older, can
meet the oral
survey in
Spanish or
English and
provide
contact
information.

Inclusion
and
exclusion
criteria

Descriptive,
bivariate, and
multivariate
analysis.
Logistic
regression &
calculation of
the total
number of
overdoses
witnessed,
experienced,
and naloxone
administration

If participants
who are likely
to witness and
act on an
overdose event
are adequately
trained, there
will likely be a
tremendous
impact on
decreasing fatal
opioid
overdoses.

Data Analysis

Study Findings

Scrutinization
of articles by
the
researchers

Success in
reversal rates
using NPP to
include
countries such
as Scotland
and several
states in the
U.S.

Prospective
observational
study

Level of Evidence (Critical
Appraisal Score) /
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Level I, Randomized Controlled
Trial, good quality.
Conclusion:
Naloxone distribution must be
prioritized.
Recommendation:
Training needs to target the
population more likely to
witness an overdose event.

Definition of abbreviations: OPT: Overdose prevention training

Mitchell & Higgins (2016)
Purpose of
Article or
Review

Conceptual
Framework

Design /
Method

Sample /
Setting

Major Variables
Studied (and their
Definitions)

Measurement
of Major
Variables

Seek to
identify the
effects of
public
access to
naloxone and
the effects on
fatal opioid
overdose

Searched
studies,
identified,
and
selected
studies to
include,
data
extracted
and
synthesized,
interpreted,
then shared
result

Literature
Review

Scholarly search
engines.

The trend globally,
U.S. OEPs with the
distribution of
naloxone,
naloxone
distribution
barriers, political
opposition and
support, financial
impact, and
recommendations.

Inclusion and
Exclusion
criteria

38 articles from
Scotland,
Canada, and
United States.
Systemic
approach.

Definition of abbreviations: OEP: Overdose Education Programs

Level of Evidence (Critical
Appraisal Score) /
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
LeveI V, good quality literature
review
The method of article selection
was not objective; hence
important article may have been
omitted. Recommended
intranasally naloxone due to its
safety, protocol implementation
for naloxone distribution,
legislative reform, and holistic
approach in preventing
overdoses
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Evaluation Table (continued)

Wheeler et al. (2015)
Purpose of
Article or
Review

Conceptual
Framework

To
determine
the effects of
NPP on fatal
opioid
overdoses
from 19962014

Survey,
Conceptual

Design /
Method

Literature
Review

Sample /
Setting

Major Variables
Studied (and their
Definitions)

Measurement of
Major Variables

The United
States,
HRC surveys

152,283 Naloxone
kits and
laypersons,
136 organizations
in the U.S.

152,283
Naloxone kits and
laypersons,

Data Analysis

Survey
responses,
Histogram.

Study
Findings

Opioid
overdose
training and
naloxone kits
provided to
layperson
likely to
observe an
overdose can
reduce fatal
overdose.

Level of Evidence
(Critical Appraisal
Score) /
Worth to Practice /
Strengths and
Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Level III good quality
literature review.
Further studies are
recommended to
include layperson likely
to witness the
overdose.

Definition of abbreviations:
HRC: Harm Reduction Coalition

Ogeil et al. (2018)
Purpose of
Article or
Review

To reveal the
effects of
THN on the
impact of
fatal opioid
overdoses

Conceptual
Framework

Retrospective
review,
Theoretical,
Conceptual

Design /
Method

Sample /
Setting

Major Variables
Studied (and
their
Definitions)

Measurement
of Major
Variables

Retrospective
review,

N=125,
69.6% males
and 30.4%
females,
South-Eastern
Australia

Males with age
ranges from 1665 years.
Females with an
age range from
22-63 years.
Overdose
deaths record

Age, Sex,
Overdose death
records

Data Analysis

Descriptive
statistics

Study
Findings

To reduce
fatal opioid
overdose,
overdose
education
should be
provided to
laypersons,
including
families.

Level of Evidence
(Critical Appraisal
Score) /
Worth to Practice /
Strengths and
Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Level III good quality
evidence.
NPP is not worth the
practice as there were
underreported data.
However, further
studies are
recommended to
include candidates
who will not withhold
valuable information.
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Evaluation Table (continued)

Furlan et al. (2018)
Purpose of
Article or
Review

Conceptual
Framework

Design /
Method

Sought the
correlation
between
approaches to
monitor the
proper use of
opioids and
reducing fatal
opioid
overdoses.

Searched
studies,
identified,
and selected
studies to
include, data
extracted
and
synthesized,
interpreted,
then shared
result

Systematic
Review

Sample /
Setting

Major
Variables
Studied (and
their
Definitions)

65
studies

65 studies

Measurement
of Major
Variables

Greylist, 65
studies

Data Analysis

PRISMA
checklist.
A systematic
qualitative
review
including
Cohen’s d

Study
Findings

Naloxone
distribution
was the
most
common
approach
to
decreasing
fatal opioid
overdoses
with largely
positive
feedback.

Level of Evidence (Critical Appraisal
Score) /
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /
Level II high-quality systematic review
of peer reviews and grey literature.
Some limitations were selection bias
and issues with participants'' follow-up.
One study reported a 39% dropout rate,
and another lacked a description of the
formulation of the various groups in the
studies. Further studies are
recommended to include
adequate descriptions of the study
groups, overall limiting risk for bias.

Mueller et al. (2015)
Purpose of
Article or
Review

Sought to
reveal the
effects of
community
naloxone
prescription
Program on
opioid
overdose.

Conceptual
Framework

Searched
studies,
identified, and
selected
studies to
include, data
extracted and
synthesized,
interpreted,
then shared
result.
Conceptual

Design /
Method

Literature
review

Sample /
Setting

N=41
articles
obtained
from
PubMed.

Major
Variables
Studied (and
their
Definitions)

Measurement
of Major
Variables

Data
Analysis

Study Findings

Level of Evidence (Critical Appraisal Score)
/
Worth to Practice /
Strengths and Weaknesses /
Feasibility /
Conclusion(s) /
Recommendation(s) /

41 studies,
NPP,
THN

41 studies,
NPP,
THN

PRISMA

One study
found that
naloxone
administration
was effective
with an 86%
reversal rate,
another
reported an
80% reversal
rate.

level III good quality literature
review.
Some limitations were related to
witnesses not being comfortable
administering naloxone, prescribers not
willing to prescribe naloxone, and under
the report of data due to
possible legal implications associated with
reporting to law enforcement.
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Appendix D
Gap Analysis

Gap Analysis

Current State

Fatal opioid
overdose is a
growing
concern in the
United States.
Increasing
opioid
overdose
rates in
Alameda
County. At
risks clients
have no
educational
program on
naloxone.

Desired State

Increase
knowledge
and
confidence on
the use of
naloxone

Gap

Need for
naloxone
educational
sessions

Developmental
Plan

Implementing
naloxone
educational
sessions
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Appendix E
Gantt Chart
Tasks
Hold a meeting with the chief executive officer (CEO)/medical
director of East Bay Pain Management to achieve a buy-in;
formulate a committee with the medical director and
psychiatric assistant.
Gather educational material on administering naloxone in
English and naloxone kit.

Aug


Sep






Oct

Nov

Obtain the letter of support from the medical director before
implementing the project



Trial of the naloxone education to 40 participants: 5-10
patients per clinical day for a total of 6 weeks





Offer pre-and post-questionnaires to evaluate the
effectiveness of each session.
Perform process evaluation.





 end the
first
week on
10/18












Periodically review the appropriateness of patient training
materials.
Document/log data gathered at each visit













Maintain monitoring of outcome metrics to determine the
effectiveness of the education session
Formulate reports for stakeholders on data gathered from the
project.
Preparation of manuscript and performing the final
presentation.















Establish a measurable value that will reveal the progress of
the outcome (outcome metrics) committee meeting.

Open for any psychiatric mental health nurse practitioner
(PMHNP) student interested and willing to carry out further
studies on the topic.





Dec
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Appendix F
Work Breakdown Structure

Work Breakdown
Structure

Project
Introduction

Planning

Formulate project
plan

Finalize the timeline,
goals and objectives
of the project

Introduce project
proposal

Establish a
framework for
project

Obtain DNP
statement of
determination and
support letter

Development

Staff education and
training materials

Implementation

Data analysis and
Evaluation

Randomly select
participants

Enter result of survey
into spreadsheet

Participants
complete
preeeducation
questionnaires

Compare pre and
post education
questionnaires

Provide naloxone
education

Post education
questionnaires

Data collection

Input outcome into
comprehensive DNP
Project Report
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Appendix G
Responsibility/ Communication Matrix

DNP Project
Communication
Plan:

DNP Chair, Dr.
Trinette Radasa and
DNP Student

DNP Committee
Members and DNP
Student

Site Medical
Director/Clinic Staff
and DNP Student

Communicate via
email and zoom
meetings as
needed

Communicate via
email and zoom
meetings as
needed

Communicate via
telephone and inperson
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Appendix H
SWOT Analysis
Strengths
Adult
Educational sessions are
naloxone
available to adults who
educational use prescriptions
sessions
established at East Bay
Pain Management
Participants likely to
witness an opioid
overdose event will gain
knowledge and
confidence

Weaknesses
Participants likely to
witness an opioid
overdose and act on it
might not want to
partake in the
educational sessions

Opportunities
Increase knowledge
on naloxone’s
potential on
decreasing fatal
opioid overdoses

Participants fear legal
issues due to limited
knowledge about the
Good Samaritan Law
in California.

The sessions increase
participants'
confidence in
identifying an
overdose event and
acting on it.

Clinic against the
proposal.

Decrease opioid
overdose deaths

Participants needing the
opportunity to help save
lives with naloxone can
help

Language barrier

Ability to provide help
and save lives

A handout is available in
the naloxone kit for the
layperson’s
convenience.

Participants might not
want to answer calls
from an unknown
number.

Sessions will likely
decrease opioid
overdose rates

Limited stakeholders’
support.

Participants can save
family or close
friends’ lives from a
fatal opioid overdose.

Stakeholders’ support

Personalize teaching
style to ensure
effective teaching.

The convenience of
educational sessions via
telephone.

The convenience of
educational sessions
via telephone.

Threats
Inadequate
supplies for
demonstration
Clinic’s
operating hours
Participants
might not want
to answer calls
from an
unknown
number, limiting
the number of
participants
Project lead not
reaching the
targeted goal of
40 participants
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Appendix I
Budget (3-year proforma)
Number
needed

Unit
Cost

2021 (6 weeks)

40

$0.1

6 units: for
the first 6
weeks, then
12 units for
year 2, and
24 units for
year 3

Program Director
Nurse Practitioner
(NP)
Psychiatry/Medical
Assistant

Naloxone nasal
spray: quick start
guide.
nasal spray
formulation of
naloxone
(Narcan) kit

$4

2022 (3
months/12
weeks)
$8

2023 (6
months/24
weeks)
$16

$0

$0

$0

$0

1

$0

$0

$0

$0

1 (2 hours
per week)
1 hour
weekly

$85/hr

$0

$2040

$4080

$15/hr

$0

$180

$360

N/A
N/A
N/A
N/A

0
0
0
N/A

0
0
0
$4

0
0
0
$2228.00

0
0
0
$4456.00

Staff

Infrastructure
Building Rent
Utilities, internet
Office Supplies
Total Expenses
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Appendix J
Data Collection tools
Pre-Questionnaire: (Please circle to indicate your answer)
1.

Type of visit?
1. Office
2. Telephone

2.

What is your gender?
1. Male
2. Female
3. Bisexual
4. Other

3.

What is your ethnicity?
1. Black of African American
2. Caucasian
3. Hispanic
4. Asian
5. Other

4.

I am between the ages of:
1. 18-29
2. 30-49
3. 50-79
4. 79 and above

5.

Where county do you live?
1. Alameda
2. Contra Costa

6.

Do you use opioids?
1. Yes
2. No

7.

Do you use any unauthorized opioids?
1. Yes
2. No

8.

Name the type (s) of opioid that you use
1. Fentanyl
2. Oxycodone (Percocet)
3. Heroin
4. Hydrocodone (Norco)
5. Methadone
6. Morphine
7. Tramadol
8. Oxycontin
9. Alfentanil
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10. Codeine
11. Dilaudid

Data Collection Tools (continued)
Pre-Questionnaire Continued: (Please circle to indicate your answer)
9.

Do you use other controlled substances?
1. Yes
2. No

10. Have you ever had or witnessed an opioid overdose event?
1. Yes
2. No
11. My knowledge about naloxone and its benefits of reducing fatal opioid overdoses
More than 90% (1)
Less than 90% (0)
12. My confidence level to identify an opioid overdose event
More than 90% (1)
Less than 90% (0)
13. My confidence level to act on an opioid overdose event
More than 90% (1)
Less than 90% (0)
14. Do you know where to access naloxone in your county without the need for a prescription?
1. Yes
2. No
15. Do you know how to use naloxone?
Yes (1)
No (0)
16. Do you have a designated person in case of an overdose?
1. Yes
2. No
17. If so, has the designated person been trained how to use naloxone?
1. Yes
2. No
18. Has the pharmacist shown you how to use naloxone?
1. Yes
2. No
19. Do you know about the California Good Samaritan Law?
Yes (1)
No (0)
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Appendix K
Post-Questionnaire: (Please circle to indicate your answer)
1.

My knowledge about naloxone and its benefits of reducing fatal opioid overdoses
More than 90% (1)
Less than 90% (0)

2.

My confidence level to identify an opioid overdose event
More than 90% (1)
Less than 90% (0)

3.

My confidence level to act on an opioid overdose event
More than 90% (1)
Less than 90% (0)

4.

Demonstrate/verbalize how to use naloxone
Successful (1)
Not successful (0)

5.

I am now knowledgeable about the California Good Samaritan Law.
Yes (1)
No (0)

6.

This education was
Helpful (1)
Not Helpful (0)
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Appendix L
Naloxone Brochure (English)

\
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Appendix M
California’s Good Samaritan Law

Understanding California’s
911 Good Samaritan Law
March 2013

On January 1, 2013, California became the tenth state
to implement a “911 Good Samaritan” overdose
fatality prevention law.
It’s likely that you know someone who has been
affected by accidental overdose – since it is a leading
cause of accidental death in California. According to
the California Department of Public Health, more
Californians died from an accidental overdose death in
2009 than from motor vehicle accidents.
Many of these deaths are preventable, yet people
often fear arrest if they call 911 for help at the scene of
a suspected drug overdose. 911 Good Samaritan laws
are designed to encourage people to quickly seek
medical care for the overdose victim by providing
limited protection from arrest, charg e and/or
prosecution for low-level drug law violations.
AB 472, California’s 911 Good Samaritan law, states:
“It shall not be a crime for any person who
experiences a drug-related overdose, as defined,
who, in good faith, seeks medical assistance, or
any other person who, in good faith, seeks medical
assistance for the person experiencing a drugrelated overdose, to be under the influence of, or
to possess for personal use, a controlled
substance, controlled substance analog, or drug
paraphernalia, under certain circumstances related
to a drug-related overdose that prompted seeking
medical assistance if that person does not
obstruct medical or law enforcement personnel.”
The law does not affect laws prohibiting the selling,
providing, giving or exchanging of drugs, or laws
prohibiting the forcible administration of drugs against
a person’s will. The law does not affect liability for any
offense that involves activities made dangerous by the

consumption of controlled substances, including, but
not limited to, driving under the influence. The law also
does not offer specific protections from arres t for
related charges, such as violation of parole or
probation.

California’s 911 Good Samaritan La w
provides limited protection from
arrest, charge and prosecution for
people who seek emergency medical
assistance at the scene of a
suspected drug overdose.
People seeking the protections provided by the law
must not obstruct medica l or law enforcement
personnel, including efforts to secure the sce ne or
deliver medical assistance.
While the definition of “possess for personal use” may
vary, the law is designed to protect people who
possess small amounts of drugs not in quantities that
would suggest trafficking or sales. A similar law to
protect minors from alcohol-related charges was
passed in California in 2010 (AB 1999, Portontino).
Other states with 911 Good Samaritan laws include:
New Mexico (2007), Washington (2010), Connecticut
(2011), New York (2011), Colorado (2012), Illinois
(2012), Florida (2012), Massachussets (2012), Rhode
Island (2012), as well as the District of Colu mbia
(2012).
California’s 911 Good Samaritan law was supported by
a varirty of organizations, including the California
Society of Addiction Medicine, the Health Officers
Association and the ACLU.

Drug Policy Alliance | 3470 Wilshire Bl vd., Suite 618 I Los Angeles, CA 90010
la@drugpolicy.org | 213.382.6400
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Appendix N
Cascade of Care Model
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Appendix O
Information covered during the educational sessions
Naloxone and opioid overdose:
•
•
•
•
•
•
•
•

Opioids are drugs typically used for relief of pain
Examples: fentanyl, oxycodone, heroin, hydrocodone, methadone
Naloxone is an effective and safe medication to reverse opioid overdose.
Naloxone is not addictive and is not harmful to anyone, including the person administering it
Forms of naloxone: nasal spray, auto-injector, injectable from the vial via syringe
Many overdoses are due to mixing opioids with other drugs such as sleeping aids, benzodiazepines, alcohol.
Other causes of overdose are strength and purity of the drug, changing the mode of administration such as
from snorting to injecting, physical health, tolerance to the drug, using while alone
A person is high or sedated and not experiencing overdose if they have: relaxed muscles, slow or slurred
speech, looking sleepy, nodding off, or does not respond to stimulations such as pinching, yelling, sternal
rub

•

Signs of overdose:
Deep snoring, gurgling, or wheezing
Blue or grayish skin tinge skin
Generally, the lips or fingertips get dark first
Pale, clammy skin
The person does not respond to stimulations
Prolonged, irregular, or no breathing
Faint pulse

•

A checklist that should be followed in the event of an opioid overdose:
1. Check responsiveness (rubbing sternum, yelling, pinching)
2. If the person is unresponsive, administer naloxone and call 9-1-1 and states the person is not
breathing, unresponsive and that you suspect a possible overdose
3. While waiting for emergency medical services, give rescue breathing and CPR (if trained in CPR, use
mouth shield)
4. Place the person in the recovery position to prevent choking
5. Administer aftercare
Wait for a full 2 minutes before you administer the second dose of naloxone. If done before, it may
exacerbate the withdrawal symptoms such as violent reaction when a person is waking from an overdose
Effects of naloxone can last between 20-90 minutes
Persons who call 9-1-1 and administer naloxone are protected from liability based on California’s Good
Samaritan Law.
Where to get naloxone:
https://www.accma.org/Portals/0/assets/docs/accma-naloxone-distribution-list-revised5%20(1).pdf?ver=2020-08-28-113627-327&timestamp=1598639801523

•
•
•
•

Reference
California Department of Public Health (CDPH). (2018, August 30). Administering naloxone [Video].
https://www.youtube.com/watch?v=nurz9qPGKws
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Appendix P
Nola J. Pender’s Health Promotion Model
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Appendix Q
Outcome metrics

Participants randomly selceted; 5-10
patients per clinical day.

Particpants complete prequestionnaire

Educational sessions

Particpants complete postquestionnaire

Increase knowledge Particpants complete
prequestionnaire of naloxone and opioid
overdoses.Improvement of participants confidence to
identify an opioid overdose Particpants complete
prequestionnaire and act on it.

